| abstract |
REFERS TO NICOTINAMIDE-DERIVED COMPOUNDS OF FORMULA I, INCLUDING ITS PHARMACEUTICALLY ACCEPTABLE SALTS AND SOLVATES, WHERE R1 IS H, HALO, or C1-C4 ALKYL; Z IS CO or SO2; R2 IS PHENYL, BENZYL, NAPHTHYL, HETEROARYL, or C3-C8 CYCLOALKYL. THE PREFERRED COMPOUNDS ARE: SYN-5-FLUORO-N- (4 - {[5- (2-METHOXY-PHENYL) -1H-PIRAZOL-3-CARBONYL] -AMINO} -CYCLOHEXYL) -2- (TETRAHYDRO-THIOPYRAN-4 -ILOXY) -NICOTINAMIDE; (4 - {[5-FLUORO-2-TETRAHYDRO-THIOPYRAN-4-ILOXI) -PYRIDIN-3-CARBONYL] -AMINO} CYCLOHEXYL) -AMIDE OF THE ACID SYN-7-METOXY-IMIDAZO [1,2-a] PYRIDIN -8-CARBOXYL; SYN-5-FLUORO-N- {4 - {[2- (2-HYDROXY-ETOXY) -BENZOYLAMINE] -CYCLOHEXIL} -2- (TETRAHYDRO-THIOPYRAN-4-ILOXI) -NICOTINAMIDE; AMONG OTHERS. IT ALSO REFERS TO A PREPARATION PROCEDURE AND A PHARMACEUTICAL COMPOSITION. THESE COMPOUNDS ARE INHIBITORS OF PHOSPHODIESTERASE PDE4 |